SchultzJLOgilvieACHarshmanLA,et al.beta-Blocker use and delayed onset and progression of Huntington disease. [published online December 2, 2024]. JAMA Neurol2025; 82(1): 85–92.
2.
AndrichJSchmitzTSaftC, et al.Autonomic nervous system function in Huntington’s disease. J Neurol Neurosurg Psychiatry2002; 72: 726–731.
3.
KobalJMelikZCankarK, et al.Autonomic dysfunction in presymptomatic and early symptomatic Huntington’s disease. Acta Neurol Scand2010; 121: 392–399.
4.
SchultzJLHarshmanLAKamholzJA,et al.Autonomic dysregulation as an early pathologic feature of Huntington disease. Auton Neurosci2021; 231: 102775.
5.
DrayerDE. Lipophilicity, hydrophilicity, and the central nervous system side effects of beta blockers. Pharmacotherapy1987; 7: 87–91.
6.
Pereira-LeiteCCarneiroCSoaresJX, et al.Biophysical characterization of the drug membrane interactions: the case of propranolol and acebutolol. Eur J Pharm Biopharm2013; 84: 183–191.
7.
EckmannJClemensLEEckertSH, et al.Mitochondrial membrane fluidity is consistently increased in different models of Huntington disease: restorative effects of olesoxime. Mol Neurobiol2014; 50: 107–118.
8.
GomesACostaDLimaJLFC,et al.Antioxidant activity of beta blockers: an effect mediated by scavenging reactive oxygen and nitrogen species?Bioorg Med Chem2006; 14: 4568–4577.
9.
MatthewsJCBakerJK. Effects of propranolol and a number of its analogues on sodium channels. Biochem Pharmacol1982; 31: 1681–1685.
10.
WangDMistryAMKahligKM, et al.Propranolol blocks cardiac and neuronal voltage-gated sodium channels. Front Pharmacol2010; 31: 144.
11.
OyamaFMiyazakiHSakamotoN, et al.Sodium channel beta4 subunit: down-regulation and possible involvement in neuritic degeneration in Huntington's disease transgenic mice. J Neurochem2006; 98: 518–529.
12.
EberOBuchingerWLindnerW, et al.The effect of D- versus L-propranolol in the treatment of hyperthyroidism. Clin Endocrinol (Oxf.)1990; 32: 363–372.
13.
SteffensmeierJJGErnstMEKellyM,et al.Do randomized controlled trials always trump case reports? A second look at propranolol and depression. Pharmacotherapy2006; 26: 162–167.
14.
AzizNAPijlHFrölichM, et al.Altered thyrotropic and lactotropic axes regulation in Huntington's disease. Clin Endocrinol (Oxf.)2010; 73: 540–545.
15.
TurossNPatrickRL. Effects of propranolol on catecholamine synthesis and uptake in the central nervous system of the rat. J Pharmacol Exp Ther1986; 237: 739–745.
16.
CunnaneJGBlackwoodGW. Psychosis with propranolol: still not recognized?Postgrad Med J1987; 63: 57–58.
17.
SchultzJLKamholzJAMoserDJ, et al.Substance abuse may hasten motor onset of Huntington disease: evaluating the Enroll-HD database. Neurology2017; 88: 909–915.
18.
SchultzJLNopoulosPCKilloranA,et al.Statin use and delayed onset of Huntington’s disease. Mov Disord2019; 34: 281–285.
19.
OgilvieACSchultzJL. Memantine use and cognitive decline in Huntington's disease: an Enroll-HD study. Mov Disord Clin Pract2023; 10: 1120–1125.
